Half-year report · HY
2342.TEDINET S100WYWR
Period2025-04-01 → 2025-09-30
Filed2025-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥6.2bn | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥13.0bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥6.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥71m | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | −¥111m | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥83m | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | −¥320m | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥157m | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥57m | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | −¥195m | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥30m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥1.1bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥182m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥11m | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | −¥185m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥9.6bn | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥9.6bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥10.6bn | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥4.8bn | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥4.7bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥4.9bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥4.9bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥5.8bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.2bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.6bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.2bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.5bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.2bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥2.5bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥569m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥94m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥421m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥36m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥288m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥175m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥261m | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥265m | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥379m | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥1.77 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-65.51 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-10.97 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 49.8% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 49.7% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 53.5% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 30
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥3m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥3m |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | −¥98m |
| Drug Discovery Support Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥938m |
| Drug Discovery Support Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥935m |
| Drug Discovery Support Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥3m |
| Drug Discovery Support Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥75m |
| Investments And Consulting Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥5.3bn |
| Investments And Consulting Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥5.3bn |
| Investments And Consulting Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥62,000 |
| Investments And Consulting Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥245m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥6.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥6.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥3m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥170m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥3m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥3m |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥114m |
| Drug Discovery Support Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥806m |
| Drug Discovery Support Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥803m |
| Drug Discovery Support Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥3m |
| Drug Discovery Support Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | −¥189m |
| Investments And Consulting Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥5.5bn |
| Investments And Consulting Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥5.5bn |
| Investments And Consulting Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥45,000 |
| Investments And Consulting Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥192m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥6.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥6.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥3m |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥3m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 508
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of shares held | InterimInstant_No2MajorShareholdersMember | 404000 | |
| Shareholding ratio | InterimInstant_No2MajorShareholdersMember | 0.0242 | |
| Number of shares held | InterimInstant_No3MajorShareholdersMember | 195412 | |
| Shareholding ratio | InterimInstant_No3MajorShareholdersMember | 0.0117 | |
| Number of shares held | InterimInstant_No4MajorShareholdersMember | 187500 | |
| Shareholding ratio | InterimInstant_No4MajorShareholdersMember | 0.0112 | |
| Number of shares held | InterimInstant_No5MajorShareholdersMember | 173000 | |
| Shareholding ratio | InterimInstant_No5MajorShareholdersMember | 0.0103 | |
| Number of shares held | InterimInstant_No6MajorShareholdersMember | 161400 | |
| Shareholding ratio | InterimInstant_No6MajorShareholdersMember | 0.0096 | |
| Number of shares held | InterimInstant_No7MajorShareholdersMember | 160200 | |
| Shareholding ratio | InterimInstant_No7MajorShareholdersMember | 0.0096 | |
| Number of shares held | InterimInstant_No8MajorShareholdersMember | 150000 | |
| Shareholding ratio | InterimInstant_No8MajorShareholdersMember | 0.0090 | |
| Number of shares held | InterimInstant_No9MajorShareholdersMember | 136900 | |
| Shareholding ratio | InterimInstant_No9MajorShareholdersMember | 0.0082 | |
| Number of shares held | InterimInstant_No10MajorShareholdersMember | 120700 | |
| Shareholding ratio | InterimInstant_No10MajorShareholdersMember | 0.0072 | |
| Number of shares held | InterimInstant | 2102730 | |
| Shareholding ratio | InterimInstant | 0.1262 | |
| Number of shares issued shares voting rights | InterimInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | InterimInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | InterimInstant_OrdinarySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 345900 | |
| Number of shares issued shares voting rights | InterimInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 16644500 | |
| Number of voting rights issued shares voting rights | InterimInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 166445 | |
| Number of shares issued shares voting rights | InterimInstant_OrdinarySharesSharesLessThanOneUnitMember | 8741 | |
| Number of shares issued shares voting rights | InterimInstant | 16999141 | |
| Number of voting rights issued shares voting rights | InterimInstant | 166445 | |
| Number of shares held in own name treasury shares etc | InterimInstant_Row1Member | 345900 | |
| Number of shares held in others names treasury shares etc | InterimInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | InterimInstant_Row1Member | 345900 | |
| Shareholding ratio treasury shares etc | InterimInstant_Row1Member | 0.0203 | |
| Number of shares held in own name treasury shares etc | InterimInstant | 345900 | |
| Number of shares held in others names treasury shares etc | InterimInstant | － | |
| Total number of shares held treasury shares etc | InterimInstant | 345900 | |
| Shareholding ratio treasury shares etc | InterimInstant | 0.0203 | |
| Cash and deposits | Prior1YearInstant | 2555397000 | JPY |
| Cash and deposits | InterimInstant | 2212390000 | JPY |
| Notes and accounts receivable trade and contract assets | Prior1YearInstant | 1195011000 | JPY |
| Notes and accounts receivable trade and contract assets | InterimInstant | 996249000 | JPY |
| Electronically recorded monetary claims operating ca | Prior1YearInstant | 22970000 | JPY |
| Electronically recorded monetary claims operating ca | InterimInstant | 222346000 | JPY |
| Merchandise and finished goods | Prior1YearInstant | 1348725000 | JPY |
| Merchandise and finished goods | InterimInstant | 1767013000 | JPY |
| Work in process | Prior1YearInstant | 796709000 | JPY |
| Work in process | InterimInstant | 903898000 | JPY |
| Raw materials and supplies | Prior1YearInstant | 76516000 | JPY |
| Raw materials and supplies | InterimInstant | 66814000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |